Carrick Therapeutics

ESMO 2021

Research

Syros targets KRAS-mutant cancer with CDK7 inhibitor

The combination of SY-5609 and gemcitabine showed near-complete tumor inhibition in mice with xenografts of KRAS-G12D pancreatic tumors.

Angus Liu Sep 20, 2021 11:30am

Prostate Cancer

A new approach to resistant prostate cancer

Aug 29, 2019 9:00am

Carrick Therapeutics CEO Tim Pearson

Carrick hires ex-Tesaro CFO, shifts focus toward U.S.

Jun 28, 2019 10:16am